Niagen Q1 2026: Modest Growth, Steady Margins, But Valuation Stays Stretched

What happened

Niagen Bioscience reported Q1 2026 net sales of $31.5 million, up just 3% year-over-year, with Tru Niagen contributing $22.4 million and gross margin holding at 63.5%. Excluding the divested Analytical Reference Standards segment, growth was a slightly healthier 5%. Net income reached $6.3 million, marking another profitable quarter, but the pace of expansion remains tepid. The core consumer supplement and ingredient business is generating reliable cash flow, but revenue growth is decelerating from the mid-teens pace seen in prior periods. Meanwhile, the pharmaceutical pipeline—the primary source of upside optionality—shows no near-term milestones, leaving the stock's ~31x P/E multiple reliant on continued, unexciting execution.

Implication

Investors should question whether the current ~$557M market cap can be justified by a ~$100M revenue base growing 3-5% organically, even with strong margins. The pharmaceutical upside from NR in Parkinson's and ataxia telangiectasia is years away and highly uncertain. Unless growth accelerates or pipeline de-risks materially, the risk/reward skews to the downside. Consider trimming positions on strength or waiting for a pullback.

Thesis delta

The Q1 2026 report reaffirms the 'POTENTIAL SELL' thesis from the master report: revenue growth is modest (3-5%), margins are stable, and free cash flow is positive but insufficient to support the high multiple. The thesis shifts slightly from 'early-stage turnaround' to 'mature, slow-growing supplement company with speculative pharma optionality.' No compelling reason to upgrade the rating until top-line growth accelerates or pharma milestones emerge.